Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 14/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL303219 | 0.93 | MAPK14 (0.46) | MAPK14PRMT5WDR77CARM1 | |
| SCHEMBL27950034 | 0.90 | NAMPT (0.40) | NAMPTMAPK14PRMT5WDR77PTGDR2 | |
| SCHEMBL303945 | 0.90 | MAPK14 (0.43) | MAPK14PTGDR2 | |
| SCHEMBL1921905 | 0.86 | TUBB4A (0.42) | NAMPTPTGDR2 | |
| SCHEMBL1922173 | 0.86 | AKR1C3 (0.41) | MAPK14PTGDR2 | |
| SCHEMBL302349 | 0.86 | LMNA (0.39) | MAPK14PTGDR2 | |
| SCHEMBL1921896 | 0.85 | PTGDR2 (0.38) | MAPK14PTGDR2 | |
| SCHEMBL302304 | 0.84 | CCNT1 (0.42) | MAPK14PTGDR2 | |
| SCHEMBL27935524 | 0.83 | MAPK14 (0.46) | MAPK14PRMT5WDR77CARM1 | |
| SCHEMBL302157 | 0.83 | PTGDR2 (0.39) | PTGDR2CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328871-B1 | HEDGEHOG PATHWAY MODULATORS | NOVARTIS AG (CH) | 2020-04-01 | — | — | EP | claimed |
| US-8507491-B2 | Compounds and compositions as hedgehog pathway inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | claimed |
| JP-2012500853-A | — | — | 2012-01-12 | — | — | JP | claimed |
| US-20110152282-A1 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2011-06-23 | — | — | US | claimed |
| EP-2328871-A2 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2011-06-08 | — | — | EP | claimed |
| WO-2010027746-A2 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2010-03-11 | — | — | WO | claimed |
| US-9216964-B2 | Hedgehog pathway modulators | NOVARTIS AG (CH) | 2015-12-22 | — | — | US | disclosed |
| US-9216964-B2 | Hedgehog pathway modulators | NOVARTIS AG (CH) | 2015-12-22 | — | — | US | disclosed |
| US-20130296333-A1 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2013-11-07 | — | — | US | disclosed |
| US-20130296333-A1 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2013-11-07 | — | — | US | disclosed |
| US-8507491-B2 | Compounds and compositions as hedgehog pathway inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-8507491-B2 | Compounds and compositions as hedgehog pathway inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-20110152282-A1 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2011-06-23 | — | — | US | disclosed |
| US-20110152282-A1 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2011-06-23 | — | — | US | disclosed |
| EP-2328871-A2 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010027746-A2 | HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296333-A1 | HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | NAMPT 4033/4885MAPK14 1462/4885PRMT5 660/4885 |
| US-20110152282-A1 | HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | NAMPT 4234/4885MAPK14 1355/4885PRMT5 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.